Regarding malignancy, key studies have reported lower rates of cancer in G6PD-deficient patients, in particular for cancers of endodermal origin (colorectal, gastric and liver malignancies) (18, 19), but a protective effect of G6PD against cancer was not found for other types of cancer and notably hematologic malignancies (20, 21). The gene discussed is G6PD; the disease is hematologic disorder.